Eli Lilly and Company $LLY Shares Sold by NTV Asset Management LLC

NTV Asset Management LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 34,250 shares of the company’s stock after selling 1,028 shares during the period. Eli Lilly and Company comprises 2.8% of NTV Asset Management LLC’s holdings, making the stock its 5th largest holding. NTV Asset Management LLC’s holdings in Eli Lilly and Company were worth $26,133,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Brown Miller Wealth Management LLC increased its holdings in Eli Lilly and Company by 1,083.8% in the third quarter. Brown Miller Wealth Management LLC now owns 3,954 shares of the company’s stock valued at $3,017,000 after purchasing an additional 3,620 shares during the period. Altfest L J & Co. Inc. lifted its holdings in Eli Lilly and Company by 31.7% during the 3rd quarter. Altfest L J & Co. Inc. now owns 13,802 shares of the company’s stock worth $10,531,000 after buying an additional 3,321 shares during the period. Grey Ledge Advisors LLC grew its position in shares of Eli Lilly and Company by 32.4% in the 3rd quarter. Grey Ledge Advisors LLC now owns 1,443 shares of the company’s stock valued at $1,101,000 after buying an additional 353 shares during the last quarter. Bourgeon Capital Management LLC grew its position in shares of Eli Lilly and Company by 82.9% in the 3rd quarter. Bourgeon Capital Management LLC now owns 23,547 shares of the company’s stock valued at $17,966,000 after buying an additional 10,676 shares during the last quarter. Finally, Physicians Financial Services Inc. increased its stake in shares of Eli Lilly and Company by 2.1% in the third quarter. Physicians Financial Services Inc. now owns 3,996 shares of the company’s stock valued at $3,049,000 after buying an additional 81 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on LLY shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Zacks Research upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Finally, Guggenheim reissued a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks upgraded LLY from Hold to Strong Buy, a near-term catalyst that can attract buying from model-driven and income-focused investors. Zacks Research upgrade
• Positive Sentiment: Articles pushing a potential “surprise dividend” narrative have resurfaced, boosting investor interest in Lilly as a must-own 2026 idea if management signals shareholder returns. Eli Lilly’s surprise dividend story could be a 2026 must-own
• Positive Sentiment: Investor write-ups (e.g., InsiderMonkey) reiterate Lilly’s strong fundamentals and leadership in GLP-1s, supporting the case for LLY as a core holding. Positive third‑party commentary can sustain buying. What Makes Eli Lilly And Co. (LLY) a Worthy Holding?
• Positive Sentiment: MarketBeat flagged Lilly’s progress advancing two additional weight‑loss drugs (one nearing approval) — successful trial/approval news would be a major upside catalyst for revenue growth. Eli Lilly’s new drug data sets up a high‑stakes 2026
• Neutral Sentiment: Broader market strength at the start of 2026 lifted many large caps, including LLY; macro momentum (vs. company-specific news) is supporting the move. MarketBeat Week in Review – 12/29 – 01/02
• Neutral Sentiment: Coverage noting price cuts for GLP‑1 drugs in China (Novo and reports of LLY pricing moves) highlights regional pricing pressure — this could temper upside but impact is currently uncertain and depends on scale. Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
• Negative Sentiment: Two recent commercials have drawn viewer backlash and accusations over messaging; while not yet a material business issue, negative publicity can affect brand perception and invite scrutiny. Company Facing Backlash For ‘Ridiculous’ Rose Bowl Commercial
• Negative Sentiment: Another piece highlights viewer division over an alleged “pro‑obesity” message in a new ad — reputational noise that could weigh on sentiment if amplified. New Eli Lilly commercial divides viewers

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,079.83 on Friday. The firm has a 50 day moving average of $1,013.16 and a 200-day moving average of $850.82. The company has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.